CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Identify the dividend Etf with the lowest tax drag and learn how tax drag affects net returns. Compare options quickly.
27,776 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
May CPI rose 0.5% from April, lifting the annual rate to 4.2%. Energy drove most of the move, while core inflation st...
Oil prices slipped Friday as investors weighed the possibility of a U.S.-Iran peace deal that could reopen the Strait...
With the MiCA grace period ending on July 1, 2026, thousands of platforms face closure or forced transfers. Millions ...
A European health-care group chief executive argues that craving work-life balance huge is a signal to reexamine job ...
As tokens getting cheaper reshape the economics of AI, companies are ramping up budgets and expanding AI deployments,...
Georgia's Sickle Cell Disease Protection Act advances with bipartisan support, directing annual Medicaid coverage rev...
Analysts outline a potential breakout path for Ethereum toward $5,000, but warn that macro headwinds and on-chain dyn...
A major biotech takeover bid sets the tone for today’s market. AbbVie’s cash offer for Apogee Therapeutics sent share...
Rocket Lab’s Victus Haze mission signals a broader shift in the space industry—from launching payloads to delivering ...
ON Semiconductor slumped about 20% after unveiling an all-stock purchase of Synaptics, triggering questions about dil...
Eight leading real estate lead generation firms rise to the top in 2026, offering AI powered insights, exclusive lead...